Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Coloplast AS's Enterprise Value is $16,606 Mil.
Coloplast AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $701 Mil. Therefore, Coloplast AS's EV-to-EBIT ratio for today is 23.68.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Coloplast AS's Enterprise Value is $16,606 Mil.
Coloplast AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1,395 Mil. Therefore, Coloplast AS's EV-to-EBITDA ratio for today is 11.90.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Coloplast AS's Enterprise Value is $16,606 Mil.
Coloplast AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $4,370 Mil. Therefore, Coloplast AS's EV-to-Revenue ratio for today is 3.80.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Coloplast AS's Enterprise Value is $16,606 Mil.
Coloplast AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $925 Mil. Therefore, Coloplast AS's EV-to-FCF ratio for today is 17.96.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Coloplast AS (OTCPK:CLPBF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Coloplast AS's current Enterprise Value is $16,606 Mil.
Coloplast AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $701 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Coloplast AS's current Enterprise Value is $16,606 Mil.
Coloplast AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,395 Mil.
Coloplast AS's current Enterprise Value is $16,606 Mil.
Coloplast AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,370 Mil.
Coloplast AS's current Enterprise Value is $16,606 Mil.
Coloplast AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,185 Mil.
Coloplast AS's current Enterprise Value is $16,606 Mil.
Coloplast AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $925 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS Enterprise Value Related Terms
Coloplast AS Enterprise Value Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBF vs ISRG, BDX, MDLN: Enterprise Value Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Coloplast AS's Enterprise Value for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBF) has a Enterprise Value of $16,606 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's Enterprise Value too high?
Coloplast AS's current Enterprise Value is $16,606 Mil. Overall, Coloplast AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Enterprise Value compare to ISRG and BDX?
Coloplast AS's Enterprise Value of $16,606 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Coloplast AS and its competitors. Coloplast AS's current Enterprise Value is $16,606 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.92, compared to a current price of $57.41 — trading 54.8% below its estimated fair value. The current Enterprise Value is $16,606 Mil. Coloplast AS's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Enterprise Value is $16,606 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $57.41 is trading 54.8% below its estimated GF Value™ of $126.92.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
Enterprise Value: $16,606 Mil
GF Value™: $126.92 vs. price of $57.41 (54.8% below fair value)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
73GF Score
Get the complete analysis for CLPBF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
